The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as young as six weeks, expanding its previous label indicated for ...

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as young as six weeks, expanding its previous label indicated for children ...

Sanofi's MenQuadfi vaccine approved by FDA for infants as young as six weeks, protecting against meningococcal bacteria strains.

May 27 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said ... The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Sanofi (NASDAQ ...

On May 23, 2025, the FDA approved an expanded indication of Sanofi's quadrivalent meningococcal vaccine MenQuadfi—for the prevention of invasive meningococcal disease (IMD) caused by Neisseria ...